{"id":436245,"date":"2025-09-25T16:49:54","date_gmt":"2025-09-25T14:49:54","guid":{"rendered":"https:\/\/www.eunews.it\/2025\/09\/25\/la-commissione-ue-autorizza-un-medicinale-per-il-trattamento-delle-fasi-iniziali-della-malattia-di-alzheimer\/"},"modified":"2025-09-25T17:58:27","modified_gmt":"2025-09-25T15:58:27","slug":"eu-commission-authorises-medicine-for-treatment-of-alzheimers-disease-early-stages","status":"publish","type":"post","link":"https:\/\/www.eunews.it\/en\/2025\/09\/25\/eu-commission-authorises-medicine-for-treatment-of-alzheimers-disease-early-stages\/","title":{"rendered":"EU Commission authorises medicine for treatment of Alzheimer&#8217;s disease early stages"},"content":{"rendered":"<p>Brussels &#8211; The European Commission has granted marketing authorisation in the EU for <strong>Kisunla<\/strong>, a medicine for the treatment of mild cognitive impairment, including mild dementia in the early stages of Alzheimer&#8217;s disease.&nbsp;<\/p>\n<p>Kisunla may help slow the progression of cognitive and functional issues&nbsp;associated with Alzheimer&#8217;s disease in some patients. The authorisation is based on <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kisunla\" target=\"_blank\" rel=\"noopener\">positive scientific assessment&nbsp;by the European Medicines Agency<\/a>, which concluded that the benefits of this medicine outweigh the risks for a specific population of patients with early-stage Alzheimer&#8217;s disease.&nbsp;<\/p>\n<p>The <a href=\"https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/index_en.htm\" target=\"_blank\" rel=\"noopener\">authorisation decision<\/a> lays down strict conditions for the use of Kisunla,&nbsp;<span style=\"margin: 0px;padding: 0px\">as<strong>&nbsp;it<\/strong><\/span><strong>&nbsp;is only deemed&nbsp;suitable for patients with a particular genetic disposition<\/strong>. Clear risk mitigation measures, such as monitoring and labelling requirements, are also outlined.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Brussels &#8211; The European Commission has granted marketing authorisation in the EU for Kisunla, a medicine for the treatment of mild cognitive impairment, including mild dementia in the early stages of Alzheimer&#8217;s disease.&nbsp; Kisunla may help slow the progression of cognitive and functional issues&nbsp;associated with Alzheimer&#8217;s disease in some patients. The authorisation is based on [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":424505,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"episode_type":"","audio_file":"","podmotor_file_id":"","podmotor_episode_id":"","cover_image":"","cover_image_id":"","duration":"","filesize":"","filesize_raw":"","date_recorded":"","explicit":"","block":"","jnews-multi-image_gallery":[],"jnews_single_post":{"format":"standard","override":[{"template":"1","parallax":"1","fullscreen":"1","layout":"right-sidebar","sidebar":"default-sidebar","second_sidebar":"default-sidebar","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"0","post_reading_time_wpm":"300","post_calculate_word_method":"str_word_count","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post_position":"meta","trending_post_label":"Trending","sponsored_post_label":"Sponsored by","disable_ad":"0","subtitle":""},"jnews_primary_category":[],"jnews_override_counter":{"view_counter_number":"0","share_counter_number":"0","like_counter_number":"0","dislike_counter_number":"0"},"footnotes":""},"categories":[25774,30961],"tags":[31029,32164],"class_list":["post-436245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-briefs","category-salute-en","tag-alzheimer-en","tag-kinsula-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/posts\/436245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/comments?post=436245"}],"version-history":[{"count":1,"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/posts\/436245\/revisions"}],"predecessor-version":[{"id":436246,"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/posts\/436245\/revisions\/436246"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/media\/424505"}],"wp:attachment":[{"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/media?parent=436245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/categories?post=436245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eunews.it\/en\/wp-json\/wp\/v2\/tags?post=436245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}